| Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre … R Stupp, ME Hegi, T Gorlia, SC Erridge, J Perry, YK Hong, KD Aldape, ... The lancet oncology 15 (10), 1100-1108, 2014 | 1028 | 2014 |
| Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial M Weller, N Butowski, DD Tran, LD Recht, M Lim, H Hirte, L Ashby, ... The Lancet Oncology 18 (10), 1373-1385, 2017 | 963 | 2017 |
| Human cytomegalovirus infection and expression in human malignant glioma CS Cobbs, L Harkins, M Samanta, GY Gillespie, S Bharara, PH King, ... Cancer research 62 (12), 3347-3350, 2002 | 882 | 2002 |
| Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma TT Batchelor, P Mulholland, B Neyns, LB Nabors, M Campone, A Wick, ... Journal of Clinical Oncology 31 (26), 3212, 2013 | 594 | 2013 |
| Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme DA Reardon, KL Fink, T Mikkelsen, TF Cloughesy, A O'Neill, S Plotkin, ... Journal of clinical oncology 26 (34), 5610-5617, 2008 | 583 | 2008 |
| Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells DA Dixon, ND Tolley, PH King, LB Nabors, TM McIntyre, GA Zimmerman, ... The Journal of clinical investigation 108 (11), 1657-1665, 2001 | 551 | 2001 |
| A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant … EA Chiocca, KM Abbed, S Tatter, DN Louis, FH Hochberg, F Barker, ... Molecular Therapy 10 (5), 958-966, 2004 | 523 | 2004 |
| Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States SA Grossman, X Ye, S Piantadosi, S Desideri, LB Nabors, M Rosenfeld, ... Clinical cancer research 16 (8), 2443-2449, 2010 | 471 | 2010 |
| Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM JM Markert, PG Liechty, W Wang, S Gaston, E Braz, M Karrasch, ... Molecular Therapy 17 (1), 199-207, 2009 | 440 | 2009 |
| HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine-and uridine-rich elements within the 3′ untranslated regions of cytokine and … LB Nabors, GY Gillespie, L Harkins, PH King Cancer research 61 (5), 2154-2161, 2001 | 396 | 2001 |
| Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma LB Nabors, T Mikkelsen, SS Rosenfeld, F Hochberg, NS Akella, JD Fisher, ... Journal of Clinical Oncology 25 (13), 1651-1657, 2007 | 374 | 2007 |
| Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology LB Nabors, J Portnow, M Ahluwalia, J Baehring, H Brem, S Brem, ... Journal of the National Comprehensive Cancer Network 18 (11), 1537-1570, 2020 | 345 | 2020 |
| A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses JM Markert, SN Razdan, HC Kuo, A Cantor, A Knoll, M Karrasch, ... Molecular Therapy 22 (5), 1048-1055, 2014 | 295 | 2014 |
| Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma AN Mamelak, S Rosenfeld, R Bucholz, A Raubitschek, LB Nabors, ... Journal of Clinical Oncology 24 (22), 3644-3650, 2006 | 282 | 2006 |
| SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma SM Robert, SC Buckingham, SL Campbell, S Robel, KT Holt, ... Science translational medicine 7 (289), 289ra86-289ra86, 2015 | 239 | 2015 |
| Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of … LB Nabors, KL Fink, T Mikkelsen, D Grujicic, R Tarnawski, DH Nam, ... Neuro-oncology 17 (5), 708-717, 2015 | 234 | 2015 |
| Treatment of relapsed central nervous system lymphoma with high-dose methotrexate SR Plotkin, RA Betensky, FH Hochberg, SA Grossman, GJ Lesser, ... Clinical cancer research 10 (17), 5643-5646, 2004 | 233 | 2004 |
| Cilengitide: an integrin-targeting arginine–glycine–aspartic acid peptide with promising activity for glioblastoma multiforme DA Reardon, LB Nabors, R Stupp, T Mikkelsen Expert opinion on investigational drugs 17 (8), 1225-1235, 2008 | 228 | 2008 |
| Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma C Happold, T Gorlia, O Chinot, MR Gilbert, LB Nabors, W Wick, SL Pugh, ... Journal of Clinical Oncology 34 (7), 731, 2016 | 209 | 2016 |
| Tumor necrosis factor α induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR LB Nabors, E Suswam, Y Huang, X Yang, MJ Johnson, PH King Cancer research 63 (14), 4181-4187, 2003 | 204 | 2003 |
